Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

NCT03786081 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

214

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor has decided to stop the trial based on strategic decisions

Conditions

Cervical Cancer

Interventions

DRUG: Tisotumab Vedotin
DRUG: Bevacizumab
DRUG: Pembrolizumab
DRUG: Carboplatin

Sponsor

Seagen, a wholly owned subsidiary of Pfizer

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]